You should contact your GP or diabetes care team if you experience: Strong, foul-smelling urine accompanied by pain or burning during urination, increased urinary frequency, or lower abdominal discomfortthese may indicate a urinary tract infection requiring antibiotic treatment according to NICE guidance (NG109)
Wegovy (semaglutide injection) is FDA-approved for: Chronic weight management in adults with a BMI of 30+ (obesity), or BMI of 27+ with at least one weight-related condition (e.g., high blood pressure, type 2 diabetes, or high cholesterol) Weight management in adolescents aged 12 and older with obesity (initial body weight 60 kg) Reducing cardiovascular risk lowering the risk of heart attack, stroke, or cardiovascular death in adults with established cardiovascular disease who are also overweight or have obesity Wegovy is meant to be used alongside a reduced-calorie diet and increased physical activity, not as a standalone treatment
Who May See Slower or Faster Responses Patients with higher baseline insulin resistance, metabolic syndrome, or type 2 diabetes may experience slower initial weight loss but more pronounced metabolic improvements over 12-16 weeks
People with obesity are more likely to have cancer and cardiovascular disease, and recent research has shown that people who use GLP-1 analogues could have a lower risk of both
Pulsed electric field (PEF) processing of chilled and frozen-thawed lamb meat cuts: relationships between sensory characteristics and chemical composition of meat